Precinical proof-of-concept demonstration of the protective effect of the Administration for 36 days of IMA001 during an acute episode of vaso-occlusion in sickle Townes HbSS mice. IMA001 reduced intravascular hemolysis and inhibited microvascular stasis in animals subjected to an acute hypoxia followed by reoxygenation (8% oxygen for 3 hours and reoxygenation at room air for 1 hour).
Imalia Reports Initial Proof-of-Concept Data for IMA001 in Sickle Cell Disease Model
Imalia reports initial proof-of-concept data for the effect of IMA001,on the progression of markers